Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DCR-STAT3 · 1 trial · 2 indications
safety and tolerability
measured according to CTCAE 5.0 criteria
| Arm | Type | Description |
|---|---|---|
| DCR-STAT3 | EXPERIMENTAL | DCR-STAT3 |
| Name | Type | Description |
|---|---|---|
| DCR-STAT3 | DRUG | DCR-STAT3 is a sterile, preservative-free solution in WFI that will be diluted in a suitable admixture diluent (0.9% normal saline) prior to IV infusion. |
Inclusion Criteria: * Age * ≥ 18 years of age inclusive, at the time of signing the informed consent. Type of Participant and Disease Characteristics \- Documented locally advanced or metastatic solid tumor malignancy or non-Hodgkin's lymphoma that is refractory to standard therapy known to provi...
DCR-STAT3 is an investigational small molecule being studied for the treatment of adults with solid tumors, including refractory tumors. It is being developed by Novo Nordisk A/S as an oncology therapeutic. It is not approved for any indication and remains in clinical development.
DCR-STAT3 is being developed by Novo Nordisk A/S, which trades under the ticker NVO. The company is the sponsor of the clinical program evaluating the small molecule in adult patients with solid tumors.
DCR-STAT3 is in Phase 1 clinical development. The program has completed one Phase 1 trial in adults with solid tumors. No Phase 2 or later studies have been reported, and the drug is not approved for any indication.
DCR-STAT3 has been evaluated in one clinical trial, NCT06098651, titled A Study of DCR-STAT3 in Adults With Solid Tumors. The Phase 1 trial enrolled 26 participants in the United States and is listed as completed. It was an uncontrolled study without randomization or blinding.
No. DCR-STAT3 is an investigational small molecule in Phase 1 clinical development and is not approved by the FDA for any indication. Its only reported trial, NCT06098651, has completed, and further clinical evaluation would be required before any regulatory review.